Teikoku Seiyaku will be responsible for the further development of Fentanyl Taifun in Japan, building on Lab Pharma’s global development plan for European and North American markets.
Under the terms of the agreement, Lab will receive a signing fee, development milestones payments and R&D reimbursements for development activities conducted by Lab in support of the development in Japan. In addition, Teikoku Seiyaku will pay Lab royalties on sales and manufacturing revenues for supplying the finished product.
“Teikoku Seiyaku, with its experience in opiate products and drug delivery differentiated products, represents an ideal partner for LAB to bring Fentanyl Taifun through clinical development and regulatory submissions in the Japanese market,” said Dr Halvor Jaeger, CEO of LAB International.
Fentanyl Taifun consists of a dry powder formulation of the pain drug Fentanyl, and is delivered by Lab’s proprietary Taifun dry powder inhaler. In recently presented clinical results, absorption of Fentanyl after a single inhalation of Fentanyl Taifun was shown to be very rapid, with an average peak concentration reached in one minute.